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ABSTRACT 
Background and aims: Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA), 
a minichromosome essential for HBV replication, is supposed to be resistant to nucleos(t)ide 
analogue treatment. We investigated the effect of long-term nucleos(t)ide analogue treatment 
on cccDNA. 
Methods: Among 129 patients who had been enrolled in previous international nucleos(t)ide 
analogue clinical trials and had liver biopsies at baseline and one year after treatment, we 
recruited 43 patients on long-term continuous treatment for 72 to 145 months for a third liver 
biopsy. Serum HBV DNA, hepatitis B surface antigen (HBsAg) levels, total intrahepatic 
HBV DNA (ihHBV DNA), cccDNA, HBV pregenomic RNA (pgRNA) as well as histologic 
changes were examined. 
Results: At the time of the third biopsy, serum HBV DNA levels were undetectable in all but 
one patient. The median levels of HBsAg, ihHBV DNA, and cccDNA were 2.88 logIU/mL, 
0.03 copies/cell, and 0.01 copies/cell, respectively. Compared to baseline levels, there was 
reduction of HBsAg levels by 0.54 log (71.46%), ihHBV DNA levels by 2.81 log (99.84%), 
and cccDNA levels by 2.94 log (99.89%), with 49% having cccDNA levels below the 
detection limit. One patient had undetectable HBsAg. The median pgRNA level, measured 
only in the third biopsy, was 0.021 copies/cell, with 40% of patients having undetectable 
pgRNA. 
Conclusions: Long-term nucleos(t)ide analogue treatment induced marked depletion of 
cccDNA in the majority of patients while serum HBsAg levels, though reduced, were 
detectable in all but one patient. Whether cccDNA depletion is sustained and associated with 
better patient outcome requires further study. 
 
Abstract word count: 250  
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LAY SUMMARY 
It is generally presumed that a form of hepatitis B virus DNA, called covalently closed 
circular DNA (cccDNA), which hides inside the nuclei of liver cells of patients with chronic 
hepatitis B, cannot be reduced by antiviral treatment. The present study showed that with 
prolonged treatment (median period 126 months), cccDNA can be markedly reduced, with 
49% of liver biopsies having undetectable cccDNA. This suggests that viral replication 
capacity would be very low after prolonged antiviral treatment. 
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INTRODUCTION 
Globally, chronic hepatitis B affects approximately 240 million people and contributes to 
more than 780,000 deaths annually [1]. Long-term nucleos(t)ide analogue treatment has been 
shown to be effective in suppression of the hepatitis B virus (HBV) replication to levels 
below the detection limits of polymerase chain reaction (PCR) assays, in histologic 
improvement (including reversal of cirrhosis), and in reducing the incidence of hepatocellular 
carcinoma [2-4].
 
Its long-term effect on intrahepatic covalently closed circular DNA 
(cccDNA) is less well documented. 
HBV is a partially double-stranded DNA virus which exists in the serum in relaxed 
circular DNA (rcDNA) form. Following binding to hepatocytes, the rcDNA viral genome is 
transported to the nucleus where the incomplete strands of HBV DNA are completed. The 
viral DNA becomes associated with cellular and viral proteins, and supercoiled into a 
cccDNA conformation. 
cccDNA is the template for transcription of HBV RNA, which is the first step of HBV 
replication. It resembles a mini-chromosome, is highly stable and resistant to nucleos(t)ide 
analogues which inhibit reverse transcription. In duck HBV (DHBV) studies, the half-life of 
DHBV cccDNA has been estimated to be 35 to 57 days [5]. The pool of cccDNA is 
maintained, and may be amplified, through transport of newly formed DNA precursors in the 
hepatocyte cytoplasm back into the nucleus. The persistence of cccDNA is a well-known 
obstacle to the cure of chronic hepatitis B [6,7]. However it has been postulated that cccDNA 
may be depleted through natural cell division and cell death with nucleos(t)ide treatment, but 
this has not been proven [8].
 
It has also been shown that while cccDNA may decrease during 
treatment, integrated viral DNA shows no discernible decrease [9]. But whether pre-existing 
integrated HBV DNA plays a role in hepatocarcinogenesis even when no new integration 
occurs with effective suppression of viral replication is uncertain. 
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Our Liver Center and other centers have demonstrated that one year of nucleos(t)ide 
analogue treatment can reduce intrahepatic HBV DNA and cccDNA [10-14]. Because of the 
requirement for serial liver biopsies, the effect of long-term nucleos(t)ide analogue treatment 
on cccDNA has seldom been investigated. The primary aim of the present study is to 
determine the degree of reduction of cccDNA as well as total intrahepatic HBV DNA 
(ihHBV DNA) and pregenomic RNA (pgRNA) in liver biopsies of patients who had been 
receiving continuous nucleos(t)ide treatment for up to 12 years. We also documented the 
histologic changes in the liver biopsies, including semi-quantitative changes in the hepatitis B 
surface antigen (HBsAg) and core antigen (HBcAg) by immunohistochemical staining. 
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METHODS 
Patients and samples 
This is a prospective study. Eligible patients included all HBsAg-positive patients 
recruited in clinical trials after 2002, with a baseline liver biopsy and a biopsy after one year 
of therapy according to the trial protocols for entecavir vs. lamivudine [15,16], telbivudine vs. 
lamivudine [17], and clevudine vs. adefovir. The last trial was prematurely terminated with 
all patients either switched to or maintained on adefovir. For inclusion in the present study, 
all patients are required to be on continuous nucleos(t)ide analogue treatment with continued 
viral suppression for over five years. Patients who had rebound of HBV DNA ≥1 log10IU/mL 
or who developed resistance as tested by the INNO-LiPA DR v3 Assay (Innogenetics, Ghent, 
Belgium) were given additional, or were switched to, appropriate nucleos(t)ide analogues for 
continued viral suppression. None of the patients had co-infection with hepatitis C, hepatitis 
D, or human immunodeficiency virus, or the presence of other forms of liver disease.  
The patients were invited to participate in the present study for a third liver biopsy. 
Throughout the period of follow-up, patients had liver function tests, HBV DNA, hepatitis B 
e antigen (HBeAg)/ antibody against HBeAg (anti-HBe) monitored every three to six months. 
All liver biopsies were either snap-frozen in liquid nitrogen or preserved in Allprotect Tissue 
Reagent (Qiagen, Hilden, Germany), followed by storage at -80°C until analysis.  
This study had been approved by the Institutional Review Board of the University of 
Hong Kong and Hospital Authority, Hong Kong West Cluster. Written informed consent was 
obtained from all patients for participating in the study and a separate consent for the liver 
biopsies. 
 
Analytical Tests  
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Serum HBV DNA was measured by the COBAS TaqMan HBV Test (Roche 
Diagnostics, Branchburg, NJ), with a lower limit of detection of 20 IU/mL. 
ihHBV DNA, cccDNA, and pgRNA were assayed by real-time PCR or real-time 
reverse transcription (RT)-PCR, as previously described [12,18,19]. Intrahepatic DNA were 
extracted from approximately 5 mg of liver biopsies using either the QIAamp DNA Mini Kit 
or the Allprep DNA/RNA/Protein Mini Kit (both from Qiagen). According to the 
manufacturer, both the QIAamp Mini kit and the Allprep Mini Kit had similar performance in 
terms of DNA extraction. Intrahepatic RNA were extracted using the Allprep 
DNA/RNA/Protein Mini Kit. 
The extracted DNA was subjected to real-time PCR quantification of ihHBV DNA 
and cccDNA using the QuantiFast Probe PCR kit in a RotorGene Q real-time PCR system 
(both Qiagen). To minimize variations in PCR quantification of the baseline, year 1, and third 
liver biopsy samples of the present study, identical real-time PCR conditions were used. 
Briefly, specific primers and fluorescence resonance energy transfer (FRET) probes targeting 
the S regions were used for ihHBV DNA detection, while those targeting the nicked region of 
the HBV DNA genome were used for cccDNA detection. Sequences of the primers and 
probes used have been described previously [12]. For cccDNA detection, the DNA samples 
were first pre-treated with Plasmid-Safe DNase (Epicenter, Madison, WI). Real-time PCR 
reaction was set up with the same PCR conditions as in ihHBV DNA detection. Serial diluted 
samples of known concentrations of a cloned HBV plasmid were included as the quantitation 
standards. The specificity and reproducibility of the cccDNA detection assay was confirmed 
using nuclear extracted DNA from cultured HepG.2.2.15 cells and archived biopsy-extracted 
DNA (Supplementary Tables 1 and 2 and Supplementary Figure 1). 
Specific primers and probes targeting to the precore regions at the start of pgRNA 
transcript were used for pgRNA detection [18,19], using the QuantiFast Probe RT-PCR Kit 
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(Qiagen). RT-PCR amplification of liver RNA was set up in the same PCR conditions as in 
ihHBV DNA detection, except that an isothermal step of complementary DNA (cDNA) 
synthesis was included before PCR amplification. Although the original primers and probes 
for real-time quantification of HBV DNA and RNA were evaluated in patients with 
genotypes A and D, only single base differences from reference genotype B and C sequences 
(the predominant genotypes in our locality) were found. 
The number of cells in the liver tissues were determined by quantification of human 
genomic DNA by the Light-Cycler Control DNA kit (Roche Diagnostics), using the β-globin 
gene as the house-keeping gene. Since intrahepatic DNA and RNA were simultaneously 
extracted from the same piece of liver tissue using the Allprep extraction kit, the amount of 
HBV DNA and RNA can be normalized against the cellular DNA content from the same 
piece of tissue. In the present study, we re-defined the lower limits of detection of the 
quantitative real-time PCR by Probit analysis using cloned HBV plasmids of known 
concentrations spiked with HepG2 hepatoma cells and taking into account the nucleic acid 
extraction process (Supplementary Figure 2). The lower limits of detection of ihHBV DNA, 
cccDNA, and pgRNA measurements were determined to be 0.001, 0.005, and 0.001 
copies/cell, respectively. 
 
Histologic analysis 
Liver biopsies for histologic examination were fixed in 10% buffered formalin and 
embedded in paraffin. Slides of 4 μm thick were stained with hematoxylin and eosin, and at 
least 1 deeper section of each biopsy was examined. Masson trichrome stain was performed 
for more accurate assessment of fibrosis.
 
Histologic grading and staging were assessed by 
pathologists who were blinded to the patient identities and drug treatment. Assessment was 
made according to the modified Knodell scoring system [20]. Assessment of non-alcoholic 
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steatohepatitis was based on the system described by Kleiner et al [21]. 
Immunohistochemical staining was performed using antibodies against HBsAg (S1-210; 
Covance. Emeryville, CA) and HBcAg (RB-1413-R7; Thermo Scientific, Fremont, CA). The 
percentage of positive staining was estimated by counting the number of positive cells against 
the background of unstained hepatocytes. 
 
Statistical analysis 
All statistical analyses were performed by using SPSS 18.0 (SPSS Inc, Chicago, IL). 
The Mann-Whitney U test was used to test continuous variables with skewed distribution. 
Related samples were tested with the paired sample t-test or the Wilcoxon Sign Ranks Test as 
appropriate. Categorical variables were tested with the Chi-square test. Correlation between 
two variables was tested using Pearson correlation analysis following logarithmic 
transformation of the skewed data. Statistical significance was defined by a p value of less 
than 0.05. 
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RESULTS 
Baseline characteristics and serological findings 
There were a total of 129 patients who participated in the three clinical trials: 
entecavir (n=20) versus lamivudine (n=18); telbivudine (n=36) versus lamivudine (n=31), 
and clevudine (n=16) versus adefovir (n=8). The allocation of the 129 patients is shown in 
Figure 1. The effects of one year of nucleos(t)ide analogue treatment in 124 of these patients 
have been previously reported [11]. Eighty-five patients were eligible for the present study 
according to the recruitment criteria. All were contacted; 43 patients consented to join the 
study and to have a third biopsy. Twenty-eight of these 43 patients were males, 15 females, 
with a median age (range) of 43 (24 to 63) years. Eleven patients had HBV genotype B and 
32 had HBV genotype C. At baseline, 23 patients were positive for HBeAg and 20 for anti-
HBe. At the time of the third biopsy, four remained positive for HBeAg, nine were negative 
for both HBeAg and anti-HBe, and 29 were positive for anti-HBe. One patient, positive for 
anti-HBe at baseline, lost HBsAg after 68 months of treatment. The median duration of 
treatment with nucleos(t)ide analogues was 126 months (range 72 to 145 months). A brief 
summary of their drug history is shown in Table 1. 
 
Histology findings 
The mean (± SD) Knodell scores of the baseline biopsy, year 1 biopsy, and the third 
biopsy were 3.88 (± 2.68), 1.26 (± 1.24), 1.35 (± 1.63) respectively (Figure 2A). Compared to 
the baseline biopsy, the year 1 biopsy and the third biopsy showed significant reduction in 
score (p<0.0001 for both), whereas there was no difference in the scores between the year 1 
biopsy and the third biopsy (p=0.759). The changes in Ishak Fibrosis score are shown in 
Figure 2B. None of the 43 patients had an Ishak score of above four at baseline. 
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Immunohistochemical staining of the third liver biopsy for HBsAg showed that 12 
patients (27.9% of the 43 patients) had 0 to 1% cells, 23 (53.3%) had 5 to 10% cells, 5 
patients (11.6%) had 20 to 30% cells staining positive, and only one patient each had 50%, 
80% and 100% cells staining positive for HBsAg. Immunohistochemical staining of the third 
biopsy for HBcAg showed that 42 patients (97%) had no cells staining positive for HBcAg 
and only one patient (2.3%) had 1% cells staining positive for HBcAg. 
 
Serum and intrahepatic findings 
The decline in serum HBV DNA, ihHBV DNA, cccDNA as well as HBsAg levels at 
baseline, one year after treatment and at the time of the third biopsy are shown in Table 2 and 
Figure 3. Compared with the baseline values, median serum HBV DNA levels decreased by 
5.15 log10IU/mL and dropped to <20 IU/mL by year 1 and remained at similar levels 
(corresponding to a 5.47 logarithmic reduction) at the time of the third biopsy (p<0.0001 
compared with baseline levels and p=0.02 comparing between levels at year 1 and at the time 
of the third biopsy). At the time of the third biopsy, all but one patient had undetectable 
serum HBV DNA. The remaining patient, on telbivudine treatment, had a serum HBV DNA 
level of 3.48 logIU/mL, and was changed to tenofovir monotherapy shortly after the liver 
biopsy. 
Median ihHBV DNA levels declined by 1.91 log (corresponding to a 98.77% 
reduction from baseline) by year 1 and further declined by the time of the third biopsy (2.81 
log or 99.84% reduction from baseline; p<0.0001 for all comparisons). Median cccDNA 
levels declined by 1.03 log (90.77% reduction) by year 1 and further declined at the time of 
the third biopsy (2.94 log or 99.98% reduction from baseline; p<0.0001 for all comparisons). 
Twenty one patients (49%) had cccDNA levels below detection limit (<0.005 copies/cell) in 
the third biopsy. Twenty-four patients had a peak alanine aminotransferase (ALT) levels of 
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>5 times the upper limit of normal (ULN). There was a slightly higher proportion of patients 
with undetectable cccDNA (15/24; 63%) in patients with peak ALT >5× ULN than in 
patients with peak ALT ≤5× ULN (6/19; 32%; p=0.088). Patients with positive HBeAg at 
baseline had higher cccDNA levels than HBeAg-negative patients. At the third biopsy, the 
cccDNA levels were comparable regardless of the baseline HBeAg-status and whether 
patients had treatment-related HBeAg-seroconversion (Supplementary Tables 3 and 4). 
In contrast, median serum HBsAg levels declined by only 0.097 log (19.97% 
reduction) by year 1 (p=0.398 compared to baseline levels), and there was only a 0.54 log 
reduction (71.46% reduction from baseline) at the time of the third biopsy (p<0.0001 
compared to both the baseline and year 1 levels). Only one patient had undetectable serum 
HBsAg at the time of the third biopsy. The decline in HBsAg levels was both slower and to a 
lesser degree compared to the decline of ihHBV DNA and cccDNA. Also the median serum 
HBsAg levels was 2.70 log10 IU/mL (range: -1.30 to 3.85) in the 35 patients with ≤10% cells 
staining positive for HBsAg in the third liver biopsies. This was lower than the median serum 
HBsAg levels of 3.00 log10 IU/mL (range: 2.68 to 3.92) in the 8 patients with >10% cells 
positive for HBsAg (p=0.046). 
Median HBV pgRNA levels, measured only in RNA extracted from the third liver 
biopsies, was very low, 0.021 copies/cell (range: 0.003 to 1.53 copies/cell), with 17 patients 
(40%) having undetectable pgRNA. Of the 21 patients with undetectable cccDNA in the third 
biopsy 12 (57%) also had undetectable pgRNA. The remaining nine patients had pgRNA 
levels ranging from 0.0074 to 0.44 copies/cell. Of the 17 patients with undetectable pgRNA 
in the third biopsy, 12 (71%) also had undetectable cccDNA. The remaining five patients had 
cccDNA levels ranging from 0.005 to 0.078 copies/cell. 
In the patients with undetectable cccDNA and/or undetectable pgRNA levels in the 
third biopsy, which can be interpreted as reflecting very little or no viral replication activity, 
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there were still high levels of HBsAg in the serum. The levels of serum HBsAg in the patients 
with undetectable cccDNA and/or pgRNA did not differ from the patients with detectable 
cccDNA and/or pgRNA levels (Table 3). This suggests that by the time of the third liver 
biopsies, the serum HBsAg levels were independent of viral replication. This is further shown 
by the correlation between cccDNA levels and serum HBsAg levels at baseline, year 1 and at 
the time of the third biopsies (Figure 4). At baseline, though the scatter of HBsAg levels was 
large, there was still a significant correlation between serum HBsAg levels and cccDNA 
levels (p=0.037, r=0.319 due to the large scatter). This correlation was lost at year 1 and at 
the time of the third biopsy (p=0.096 and 0.209 respectively). This suggests that before 
treatment, serum HBsAg levels might partly reflect viral replication. But as viral replication 
became suppressed through reverse transcription inhibition (year 1) and then through 
depletion of cccDNA (by the time of the third biopsy), serum HBsAg continued to be 
produced despite low or even no viral replication. 
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DISCUSSION 
cccDNA, the viral mini-chromosome template for HBV RNA transcription, is 
supposed to be resistant to treatment with nucleos(t)ide analogues (reverse transcriptase 
inhibitors), and is replenished and amplified from newly formed cytoplasmic HBV rcDNA. 
Clearance of cccDNA has been defined as a “cure” for chronic hepatitis B [6]. The current 
study is the first study to document that long-term (more than 6 years) nucleos(t)ide analogue 
treatment could profoundly reduce the amount of cccDNA from the median baseline level of 
7.28 copies/cell to 0.57 copies/cell (90.77% reduction) after 1 year, and to 0.005 copies/cell 
(99.89% reduction from baseline) after a median treatment duration of 126 months. The rapid 
reduction in the first year of treatment has been previously reported in other studies [11-14], 
and it may reflect the decline in cccDNA replenishment and amplification with effective 
inhibition of reverse transcriptase activity. The further reduction with longer periods of 
treatment may be attributable to natural cell death and cell division of the hepatocytes as has 
been postulated by Mason et al [8], so that 49% of patients had cccDNA levels below the 
detection limit by the time of the third biopsy. The finding that patients with higher peak 
ALT levels tended to have a higher chance of undetectable cccDNA also supports the 
postulation that cccDNA reduction is related to increased cell turnover. 
HBV pgRNA levels were also very low, with 40% of patients having HBV pgRNA 
levels below the detection limit at the time of the third biopsy. However there were patients 
who had cccDNA levels below detection limit while having detectable pgRNA, or vice versa. 
This indicates that having cccDNA or pgRNA levels below detection limits may not signify 
complete “clearance” of these entities. This is similar to the situation of “HBsAg 
seroclearance”, where HBsAg can still be detected in a substantial proportion of patients with 
more sensitive assays [22], and where severe, and even fatal, reactivations can occur with 
potent immune suppressors like rituximab [23]. At the time of the third biopsy, ihHBV DNA 
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was still detectable in all patients, but was reduced by 99.84% to a low median level of 0.35 
copies/cell. This low level of ihHBV DNA could be attributed to the presence of integrated 
HBV DNA, which was measured as a part of ihHBV DNA by our assay. The marked 
reduction of ihHBV DNA together with cccDNA and pgRNA suggest that with long-term 
nucleos(t)ide analogue treatment, the capacity for viral replication could be suppressed to an 
extremely low level. 
Consistent with other studies [11,24-26], the decline in serum HBsAg levels was 
much slower and more variable than the decline in cccDNA and ihHBV DNA. Two findings 
suggest that under long-term nucleos(t)ide analogue treatment, HBsAg continued to be 
produced independent of viral replication. First, serum HBsAg levels at the time of the third 
liver biopsies, though lower than at baseline and after one year of treatment, were the same 
irrespective of whether the patients had detectable or undetectable cccDNA or HBV pgRNA 
(Table 3). Second, there was a positive correlation between HBsAg levels and cccDNA levels 
at baseline (p=0.037). This correlation became only a trend by year 1 (p=0.096) and was 
completely lost by the time of the third biopsies (p=0.209) (Figure 4). It has been suggested 
that HBsAg can be produced either from replication-inactive but transcription-active cccDNA 
or from integrated HBV DNA [9,25]. As proposed by Chevaliez et al [25], we postulate that 
the relatively slow decline of HBsAg levels is due to the expression of HBsAg from 
integrated HBV DNA. Chevaliez et al calculated from their study that the median year to 
“clear” HBsAg was 52.2 years [25]. Histologic findings in the third biopsies revealed that 
more than 80% of patients had ≤10% cells staining positive for HBsAg. This finding is in 
marked contrast to that in untreated patients, in whom there is often abundant hepatocyte 
cytoplasmic HBsAg, even in the non-replicative phase of infection [27]. The reason for the 
discrepancies between the intrahepatic and serum HBsAg expressions is not known. But the 
immunohistochemical detection of HBsAg in histology sections is much less sensitive than 
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serum HBsAg assays. In addition, circulating HBsAg may have a longer half-life than 
intrahepatic HBsAg. 
Since HBeAg seroconversion is often associated with post-conversion reactivation 
and development of complications of cirrhosis and HCC [28,29], the “ideal” endpoint of 
treatment at present is deemed to be HBsAg seroclearance [30]. However HBsAg 
seroclearance is only achievable in 10 to 12% of patients with current treatment agents. If 
HBsAg particles are produced in the host hepatocytes even when there is no active viral 
replication, and the findings of the present study supported this view, then HBsAg 
seroclearance may never be achievable in the majority of patients. There have been only very 
few studies on the reduction of cccDNA with long-term treatment [31,32]. Whether it is 
possible to completely eradicate cccDNA in all patients with longer therapy is uncertain. 
While there were discrepancies between different studies in the magnitude of cccDNA 
reduction upon long-term treatment [31,32], our present study showed that cccDNA was 
depleted after more than 6 years of treatment, with 49% of patients having cccDNA levels 
below the assay detection limit. To establish cccDNA depletion as a potential endpoint of 
treatment, further studies are required to determine whether cccDNA depletion is sustainable 
after cessation of treatment as well as associated with better long-term outcome for the 
patients. 
Our study is the only study to date to quantitate the changes of ihHBV DNA and 
cccDNA in human subjects with more than 6 years continuous viral suppression with 
nucleos(t)ide analogue treatment. It documented, for the first time, that both ihHBV DNA 
and cccDNA could be markedly reduced with such treatment. It disproves the standard 
concept that cccDNA is “resistant” to nucleos(t)ide analogue therapy. Furthermore, our study 
also gave evidence that HBsAg could still be produced despite absence of viral replication as 
indicated by undetectable cccDNA and pgRNA. Besides HBsAg, our group and others have 
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demonstrated the use of other serum markers such as serum HBV RNA [33] or hepatitis B 
core-related antigen (HBcrAg) [34-36] for the monitoring of HBV activities. Further studies 
of HBcrAg levels will be performed in our patients to determine whether there is any 
correlation between HBcrAg and cccDNA levels. 
One of the limitations of the present study is the limited (three) time points and the 
relatively small number of patients for the estimation of the cccDNA and ihHBV DNA levels 
and the lack of baseline and year 1 samples for immunohistochemical detection of HBsAg 
and HBcAg. Secondly, a control arm of untreated HBeAg-positive patients was not available 
to study the effect of HBeAg seroconversion on cccDNA reduction. Therefore it is difficult to 
discern to what extent cccDNA reduction was related to HBeAg seroconversion. However, 
the cccDNA levels at the third biopsy did not correlate with the baseline HBeAg-status nor 
the occurrence of HBeAg-seroconversion (Supplementary Tables 3 and 4), indicating that the 
antiviral treatment may play a more important role in cccDNA reduction. Thirdly, there 
might be sampling errors with liver biopsies. 
At present, there are no commercial, standardized assays for the detection of 
intrahepatic HBV DNA and RNA. However the ihHBV DNA, cccDNA and pgRNA assays 
used in the present study are based on widely published and accepted methodology 
[12,18,19]. We have adopted the commonly used “over-gap” PCR as well as the use of 
plasmid-safe DNase for the quantitative detection of cccDNA [12]. In this “over-gap” PCR, a 
small amount of non-specific amplification of rcDNA may be present, due to the annealing of 
partial PCR products during amplification. To overcome this problem, plasmid-safe DNase 
was used to eliminate most of the non-circular DNA, including rcDNA, chromosomal DNA 
and integrated HBV DNA. Although the activity of plasmid-safe DNase on the portion of 
rcDNA molecules that have a nearly complete plus-strand is limited [6], our data showed that 
the non-specific amplification of rcDNA accounts for only less than 0.01% of the HBV DNA 
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population (Supplementary Table 1). Moreover, the limitations of the cccDNA assay 
mentioned above would only result in false positive values, and therefore not affect the low or 
undetectable values of this study. In the current study, the cccDNA assay did not detect 
cccDNA in 49% of patients at the time of the third biopsy, even allowing for potential false 
positive results. For future studies, assays with improved sensitivity, as well as assay which 
can distinguish between integrated and episomal HBV DNA, are required to more accurately 
measure the low level of intrahepatic HBV DNA in patients under long-term viral 
suppression.  
In conclusion, continuous HBV suppression with long-term nucleos(t)ide analogue 
treatment progressively reduced ihHBV DNA and cccDNA by over 99%, whereas serum 
HBsAg levels were reduced by 71%. HBV pgRNA was also below detection limit in 40% of 
patients. HBsAg seroclearance may not be achievable in the majority of patients with the 
currently available therapeutic agents. Whether cccDNA reduction or depletion is sustainable 
and associated with better outcome remain to be determined. 
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FIGURE LEGENDS 
 
Figure 1. Patient allocation. Flow chart showing the selection process of the 43 patients 
participating in the study from the 129 patients with biopsies at baseline and after one year of 
treatment. 
 
Figure 2. Summary of the histologic findings. A. The Knodell scores of the 43 patients at 
baseline, one year after treatment and at the third biopsy. B. The Ishak scores of the 43 
patients at baseline, one year after treatment and at the third liver biopsy. 
 
Figure 3. Effect of treatment on serum and intrahepatic HBV DNA and hepatitis B 
surface antigen levels. The median levels (with ranges) of serum HBV DNA, total 
intrahepatic DNA (ihHBV DNA), covalently closed circular DNA (cccDNA) and serum 
hepatitis B surface antigen (HBsAg) at baseline, after one year of treatment and at the time of 
the third liver biopsy. 
 
 
Figure 4. Correlation between serum hepatitis B surface antigen and covalently closed 
circular DNA levels. The correlation between serum HBsAg levels and covalently closed 
circular DNA (cccDNA) levels at baseline, after one year of treatment and at the time of the 
third liver biopsy. 
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Table 1. A brief summary of the drug history of the 43 patients included in the study. 
Nucleos(t)ide analogue 
treatment at baseline 
Nucleos(t)ide analogue treatment at 
last biopsy 
Number of 
patients 
Lamivudine Adefovir 2 
 Telbivudine 3 
 Entecavir 7 
 Tenofovir 2 
Adefovir Telbivudine 1 
 Entecavir 2 
Telbivudine Telbivudine 4 
 Entecavir 4 
 Tenofovir 3 
 Lamivudine + Tenofovir 1 
Entecavir Entecavir 9 
Clevudine Entecavir 5 
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Table 2. HBV DNA, intrahepatic total HBV DNA, cccDNA and serum HBsAg levels at baseline, after 1 year of treatment and at the time of the 
third biopsies. 
 Baseline After 1 year of treatment At the time of third biopsies 
Serum HBV DNA, log IU/mL*  6.92 (4.27 – 11.9) <1.30 (<1.30 – 10.56) <1.30 (<1.30 – 3.48) 
Logarithmic reduction†  - 5.15 log 5.47 log 
Percentage reduction† - >99.99% >99.99% 
Intrahepatic total HBV DNA, copies/cell* 285.8 (0.494 – 10,223.6) 3.25 (0.038 – 12,218.2) 0.35 (0.037 – 4.65) 
Logarithmic reduction† - 1.91 log 2.81 log 
Percentage reduction† - 98.77% 99.84% 
cccDNA, copies/cell* 7.28 (0.018 – 114.5) 0.57 (<0.005 – 15.1) <0.005 (<0.005 – 2.13) 
Logarithmic reduction† - 1.03 log 2.94 log 
Percentage reduction† - 98.77% 99.89% 
Serum HBsAg, log IU/mL* 3.40 (2.07 – 5.28) 3.28 (1.79 – 5.17) 2.88 (-1.30 – 3.92) 
Logarithmic reduction† - 0.097 log 0.54 log 
Percentage reduction† - 19.97% 71.46% 
*Values are expressed as median (range); †Median reduction compared with the baseline values 
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Table 3. Median serum HBsAg levels in patients with or without detectable cccDNA and 
pgRNA at the time of the third biopsy 
 
cccDNA or pgRNA status at the third biopsy Median serum HBsAg, 
logIU/mL (range) 
p value 
Undetectable cccDNA (n=21) 2.88 (-1.3 – 3.58) 
0.68 
Detectable cccDNA (n=22) 2.81 (1.55 – 3.92) 
   
Undetectable pgRNA (n=17) 2.88 (-1.3 – 3.85) 
0.55 
Detectable pgRNA (n=26) 2.83 (1.55 – 3.92) 
   
Undetectable cccDNA and/or pgRNA (n=26) 2.81 (-1.3 – 3.85) 
0.49 
Detectable cccDNA and pgRNA (n=17) 2.97 (1.55 – 3.92) 
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